Trastuzumab conjugate - BioIntegrator

Drug Profile

Trastuzumab conjugate - BioIntegrator

Alternative Names: BI-CON-02

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioIntegrator
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 01 Sep 2016 Biointegrator initiates enrolment in a phase I trial for Breast cancer (Metastatic disease, Second-line therapy or greater) in Russia (NCT03062007)
  • 05 Jul 2016 Phase-II clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top